Clinical Trial Update: Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of autologous MSC_apceth_101 for advanced gastrointestinal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Drugs mentioned

• MSC_apceth_101

Snippet

Sponsor: Apceth GmbH & Co. KG | Conditions: Advanced Gastrointestinal Cancer | Phase 1, Phase 2 | Status: TERMINATED